Table Of Content

AUTHOR INDEX Ades, T.B., 290 Fulton, J.S., 28 Porter, S., 200 Anderson, R.W., 109 Ganschow, J.R., 99, Quinn, L.K., 60 Bailey, L.J., 154 Grant, M., 1, : Beck, S.L., 11 ; z Rieger, P.T., 276 Birenbaum, L.K., 50 Hinds, P D.; SU Rutledge, D.N., 1, 3 Bookbinder, M., 3, 36 Hubbard, S.M Bovle, D.A., 109 Hunt, J.M., 79 Schulmeister, L., . B>r» o‘ wn, I1.GG... , 305 Kamin, D.Y.f , 2655 SSpmiintelhl,i , E.AL. , 1o8s4 stnheerrryt, , C., 161677 Lajeunesse, J.D ) oportsman, 5 thristensen, A., 86 Stahl, C., 20 tondosta, D., 223 Martin, V.R., 5 Stovall, E looke, | 5 Mayet I ‘ > a : Swenson, ¢ ioons, M.. : McPhail, J.T., 28 over, M., Meier, E., 105 labano, M cawtord, K., i Middleton, G.J lemple, S Moore,P ., 27¢ Tevtelman, Y., 121 Daly, N.R., Mortenson, L Davenport-Ennis, N., 290 Vacchiano, S.A., 167 Dean, G.E., 20 O’Keete, M.E., 14. Valadez, A.M., 149 DeVita, V.T. Jr., 252 Door, A., 207 Parsons, S.K., 241 Whedon, M.B., 36 Pedrosa, A.M., 50 Wilson, B.J Fischer, M., 193 Pedrosa, F., 50 Frank-Stromborsg, M., 85, 128 Penne, K., 66 Zuk, S.M., 60 SUBJECT INDEX ACCC (Association of Community Cancer Centers), 282 \therosclerosis, smoking and, 244 286. 300 . oo ncet kins and. 2 Access to health care, barriers to, 259-2 Bladder cancer, smoking and, 244 Acquired immunodeficie. ncy syndrome advocacy, 290-292 Ba ush Aedem inistrationan,ta g. 22 3 71 ACS (American Cancer Society), 292-293, 305 79_97 Cancer advisory groups, 272-274 Advertising, tobacco-related, 246-247 Cancer Leadership Council( , 294-295, 298 Advocacy : ; “er? : incer policy. See also specific health policy issues AIDS, 290-292 a\ merican Caenacee r SocSiepty and, Le tae2 9T2a-re2e9 3 oa OisNsuSe s, infvoor lvCeomnegnrte ssin/,g o2 vernmental agencies, 242-243 Cancer Leadership (¢ ouncil and, 294-295 popt he si 4()7 current/emerging issues, 255 stmaOtpeu lag © ovoeO rnImSeSnUCtSs ) and‘ , 2a/i2n current ONS activities, 277-288 ; Sais enters for Disease Control and Preventio(n¢ future of,: <95—<90 = enters tor Medicare and Medicaid Services (CM: initiatives for, 296-297 301 National Coalition tor Cancer Survivorship and, 293-295 i as erebrovascular disease, smoking and, 244 / ONS, : history of, 2a7e7s , 278 hronie obstructive pulmonary disease, smoking and, 244 rican .Americans, 307 rett xeise tax. 249. 261 Age C ; CC ecidenee and, 2» 9-0 igarette e s| mok. inIg .~ Se+e S-2 m4o7 king S)G r: iecsr/pai cy,e Vv —2i: 9 0-2P9 e30 8 LC (Cancer Leadership Council), 2‘ 94-295, = 298 AIDS advocacy, 2 ae linical Journal of Oncology Nursing, 282 American Cancer Society (ACS) 292-293 ; ; : linical triais AAmmeerriiccaann SNoucriseetsy Atsosr oc&Ti haetriaonp eutCiocd e Roafd ioEtlhoigeys , a2n7d7 Oncology low participation I safety¢ during. , 2> 60 (ASTRO), 287, 298 ‘linton Administration, 248, 272, 301 American Society of Clinical Oncology (ASCO), 286, 298, MS (Centers for Medicare and Medicaid Services) p2r9at9t . 3z0 0 +) AoArmteicr; icaanse uryf NsCmO,L OSsYm okNiunrsge s; :a nd,A dv2)o 4c4a tes in Action,” 282 oaleivtoilon5u st.i on Seeo f. al2s9o 7aoe -s2pe9c8if iC@ cancer coalitions APON (A4 ssociati®o n of Ped. ia° tri-e > Onco> logyOo Nurses> ), 2> 86 examples of, 298 Arent Fox, 278 future of: 303-004 ASCO (A29m9e. ri3c00a n Society of Clinical Oncology), 286, 298 ppooliutitc al ¢ ji evei] opmcnt of, J1O)U -S0320) ? ongress AAssiiaann -AAmmeerriicc:a ns, J3O(E) 7 healtleht policy issues tor, 242-2431 Association of Community Cancer Centers (ACCC), 282, tobacco-related bills, 248 <) 56,f 32 00 on oronary heart d'i sease, smoking and, 244 Association of Pediatrie Oncology Nurses (APON), 286° ASTRO (American Society for Therapeutic Radiology and Daschle, Senator Tom, 283 ( cology ), 287, 298 Deaths, tobacco-related, 243, 244, 261-262 312 INDEX “The Denver Principles,” 291 Medicare Department of Defense, 269-270 as federal program, 241-242 Diagnostic Related Groups (DRGs), 299, 301 reimbursement fraud, 270-271 Diseases, smoking-related, 244, 248 reimbursement limits, 271-272 DRGs (Diagnostic Related Groups), 299, 301 Minority population, politics/policy and, 307 Mortality rates, 252-253, 254 Economic issues burden of cancer, 263 National Bioethics Advisory Commission, 260 provider, 299-300 National Cancer Act of 1971, 253, 254, 265, 297 smoking-related, 243 National Cancer Institute (NCI) Education, for ONS members, 281-283 bypass budget, 253-254, 267 Elderly, politics/poliey and, 308 cancer advisory groups, 273-274 EONS (European Oncology Nursing Society), 287 “Extraordinary Opportunities for Investment,” 267, 268 Esophageal cancer, smoking and, 244 grants, 270 European Oncology Nursing Society (EONS), 287 National Cancer Act and, 253 research budget, 274 FDA. See Food and Drug Administration research funding and, 254, 266-267 Federal Commerce Commission Fairness Doctrine, 243 National Cancer Legislation Advisory Committee (NCLAC) Federal Trade Commission (FTC), 246-247 cancer battle plan, 254-255, 305-306 Food, Drug, and Cosmetic Act, 247 challenges/recommendations for cancer care, 255-263, Food and Drug Administration (FDA) 305 authority over tobacco products, 247 National Cancer Program drug approval process, 259 challenges/recommendations tor, 2 regulatory mandate, 270 Legislation Advisory Committee members, 264 FTC (Federal Trade Commission), 246-247 legislative history, 253-254 Funding, research National Cancer Screening Initiative, 261 challenges/recommendations for, 255, 258 National Coalition for Cancer Research (NCCR), 298 National Institutes of Health and, 254, 266-268 National Coalition for Cancer Survivorship (NCCS), 293-294 special interest groups and, 302-303 National Dialogue on Cancer (NDC), 298, 303, 305, 309 Government. See also specific government agencies National Health Institutes (NIH), 260 health policy issues for, 242-243 National Institute for Environmental Health Science role in health care, 241-242 (NIEHS), 259, 269 National Institute on Aging, 268 Health Care Financing Administration (HCFA), 301 National Institute on Nursing Research, 268-269 Health care insurance, inadequate coverage, 259-260 National Institutes of Health (NIH) Health care planning, 262 cancer programs, 268-270 Health care policy. See Cancer policy funding of research and, 266-268 Health care professionals National Cancer Institute. See National Cancer Institute myths about being politically active, 283, 284 organization of, 268 shortages of, 258 National Patient Advocacy Foundation, 302 Health care system Native American health care, 262 challenges/recommendations for cancer care, 255-263 NCCR (National Coalition for Cancer Research), 298 components for cancer care, 255 NCCS (National Coalition for Cancer Survivorship), 293-294 Health Policy Tool Kit, 282 NCI. See National Cancer Institute Health Resources and Services Administration (IIRSA), 269 NCLAC. See National Cancer Legislation Advisory Health status, smoking and, 244 Committee HHS (U.S. Department of Health and Human Services), 265- NDC (National Dialogue on Cancer), 298, 303, 305, 309 266 “Negative rights,” 241 Hispanic Americans, 307 NIEHS (National Institute for Environmental Health Human immunodeficiency virus (HIV), 291-292 Science), 259, 269 NIH. See National Institutes of Health Incidence of cancer, 252-253, 261-262 Nurse in Washington Internship Program (NIWI), 280, 283 International Society of Nurses in Cancer Care (ISNCC), Nutrition, cancer-related deaths and, 262 International Union Against Cancer (UICC), 287 ISNCC (International Society of Nurses in Cancer Care), Office of Human Research Protections, 260 “Off-label” drug use, 27, 270, 299 Kidney cancer, smoking and, 244 Oncology Nursing Forum, 282 Labeling, of cigarettes, 246-247 Oncology nursing practice, scope of, 274-275 Laryngeal cancer, smoking and, 244 Oncology Nursing Society (ONS), 276, 287 Legal settlements, tobacco-related, 249-250 advocacy agenda, 279, 280 Legislation. See also specific legislation history of, 277, 278 advocacy efforts and, 295 lobbying efforts, 283-285 tobacco control, 245, 247 member education, 281-283 Longest model, 242 online legislative action center, 280-281 Lung cancer, smoking and, 244 organizational structure of, 277-278, 280-281 professional partnerships, 285-288 Mayer, Deborah K., 277 resources of, 277-278, 280-281 Medicaid volunteer members, 280 governmental authority for, 241-242 Onco-politics reimbursement fraud and, 270-271 early years of, 298-299 Medical records privacy, 271 evolution of, 297-298 INDEX 313 ONS. See Oncology Nursing Society Research community, initial involvement in policy/politics, Oral cancer, smoking and, 244 299 Routine care costs, 260-261 PAF (Patient Advocate Foundation), 296 Ryan White CARE Act, 291-292 Pain Relief Promotion Act, 283 Screenings Pancreatic cancer, smoking and, 244 Medicare-supported, 261 Patient Advocate Foundation (PAF), 296 rates among elderly, 261 Peptic ulcer disease, smoking and, 244 Second-hand smoke, protection from, 243 Policy. See Cancer policy Politics, population issues and, 307-309 SHPL (State Health Policy Liaison), 280 Smoking Population, politics/policy and, 307-309 adverse health effects of, 243, 244, 246 “Positive rights,” 241 President, cancer advisory groups and, 272-274 prevalence of, 243 PRGs (Progress Review Groups), 267-268 tobacco control etforts and, 243, 246-249 Smoking cessation programs, 261 Professional organizations Special interest groups, 302-303 evolution of political involvement, 297-298 State governments, cancer policy and, 272 fiscal restraints, 288 State Health Policy Liaison (SHPL), 280 Progress against cancer, 305-306 Survival rates, 252, 306 Progress Review Groups (PRGs), 267-268 Public Law 244, 253 Taxes, on tobaceo/tobacco-related products, 249, 261 Public policymaking model, 242 > “The Framework Convention on Tobacco Control,” 248 Tobacco control efforts, 243, 246-249 Quality of care, barriers to, 259-263 Tobacco industry, 245-246, 247-248 Tobacco-related cancers, 306 Reimbursement Tobacco settlements, 249-250 traud, 270-27 Tobacco tax, 249, 261 for quality care, 299-300 ‘Translational centers,” 258 Reporting requirements, 262-263 “ ICC (International Union Against Cancer), 287 Research United States population, politics/policy and, 307-309 agenda, 302-303 U S. Department of Health and Human Services (HHS), 265 funding. See Funding, research grants, 299 266 obstacles for, 255, 258-259 White house, cancer advisory groups and, 2